Join free webinar!

ONLY LIMITED SPOTS

By submitting this form you agree to the privacy policy.

Clinical programs in genetics: How to speed up diagnosis and accelerate treatment development?

November 30, 2021  2 PM CET (KSA: 4 PM, UAE: 5 PM)

Duration: 45 minutes

Genetics in Clinical Studies

The implication of genetic knowledge speedups clinical study outcomes.

Prevalence Studies

The prevalence studies reveal the exact number of patients with genetic diseases worldwide.

Longitudinal Studies

The constant monitoring of diagnosed patients and their families allows Metabolic Fingerprinting. This approach can distinguish the disease state from healthy controls with high accuracy and precision by analyzing a multitude of intertwined molecules at once.

Studies during COVID-19

Clinical studies can be easily done even in times of contact restrictions during COVID-19.

Clinical studies reduce a diagnostic delay, define the exact number of patients with hereditary diseases, and accelerate medication development.

During this webinar, our Sr. Director Clinical Programs, Dr. Volha Skrahina, will highlight the following:

Volha is a strong leader, highly motivated and dedicated to all partners. She started her career during her Bachelor’s thesis at the Republican Theoretical and Practical Center – ‘Mother and Child’ in Minsk, Belarus. Afterward, she investigated the translational regulation of the innate immune response in tuberculosis infection during her master’s thesis at the Max Planck Institute in Berlin, Germany. She has completed her PhD thesis on the host fungal micronutrient interaction at the Hans Knoell Institute in Jena, Germany in 2018. Until early 2021, Volha has worked as a Director of Clinical Studies at CENTOGENE. She executed plenty of observational clinical studies worldwide to analyse the prevalence of rare diseases allowing patients to be diagnosed at the earliest possible moment. Additionally, she performed longitudinal observational clinical studies to validate and monitor biomarkers required for diagnosis and treatment personalisation.

Speaker

Dr. Volha Skrahina, 
Sr. Director Clinical Programs

Volha is a strong leader, highly motivated and dedicated to all partners. She started her career during her Bachelor’s thesis at the Republican Theoretical and Practical Center – ‘Mother and Child’ in Minsk, Belarus. 

Afterward, she investigated the translational regulation of the innate immune response in tuberculosis infection during her master’s thesis at the Max Planck Institute in Berlin, Germany. She has completed her PhD thesis on the host fungal micronutrient interaction at the Hans Knoell Institute in Jena, Germany in 2018. 

Until early 2021, Volha has worked as a Director of Clinical Studies at CENTOGENE. She executed plenty of observational clinical studies worldwide to analyse the prevalence of rare diseases allowing patients to be diagnosed at the earliest possible moment. Additionally, she performed longitudinal observational clinical studies to validate and monitor biomarkers required for diagnosis and treatment personalisation. 

Speaker

Dr. Volha Skrahina, 
Sr. Director Clinical Programs

Clinical programs in genetics: How to speed up diagnosis and accelerate treatment development?

November 30, 2021  2 PM CET 

(KSA: 4 PM, UAE: 5 PM); Duration: 45 minutes

2021. All rights reserved by arcensus GmbH

2021. All rights reserved by arcensus GmbH

Clinical studies reduce a diagnostic delay, define the exact number of patients with hereditary diseases, and accelerate medication development.

During this webinar, our Sr. Director Clinical Programs, Dr. Volha Skrahina, will highlight the following: